These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 19846344

  • 1. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.
    Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, D Amelio R.
    Clin Immunol; 2010 Feb; 134(2):113-20. PubMed ID: 19846344
    [Abstract] [Full Text] [Related]

  • 2. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O.
    Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
    [Abstract] [Full Text] [Related]

  • 3. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
    Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, Cardelli P, Rossi F, D'Amelio R.
    Vaccine; 2006 Apr 12; 24(16):3217-23. PubMed ID: 16466833
    [Abstract] [Full Text] [Related]

  • 4. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC, Saxne T, Nilsson JA, Geborek P.
    Rheumatology (Oxford); 2007 Apr 12; 46(4):608-11. PubMed ID: 17114801
    [Abstract] [Full Text] [Related]

  • 5. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP.
    Ann Rheum Dis; 2008 May 12; 67(5):713-6. PubMed ID: 17965123
    [Abstract] [Full Text] [Related]

  • 6. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
    Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.
    Arthritis Res Ther; 2011 May 12; 13(6):R209. PubMed ID: 22177419
    [Abstract] [Full Text] [Related]

  • 7. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O.
    Ann Rheum Dis; 2006 Feb 12; 65(2):191-4. PubMed ID: 16014674
    [Abstract] [Full Text] [Related]

  • 8. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL, Kivitz AJ, Birbara C, Luo AY.
    J Rheumatol; 2007 Feb 12; 34(2):272-9. PubMed ID: 17304653
    [Abstract] [Full Text] [Related]

  • 9. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.
    Arthritis Rheum; 2010 Jan 12; 62(1):75-81. PubMed ID: 20039396
    [Abstract] [Full Text] [Related]

  • 10. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct 12; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 11. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group.
    J Rheumatol; 2007 Aug 12; 34(8):1670-3. PubMed ID: 17611987
    [Abstract] [Full Text] [Related]

  • 12. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun 12; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec 12; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 14. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M.
    Recenti Prog Med; 2006 Mar 12; 97(3):134-9. PubMed ID: 16700418
    [Abstract] [Full Text] [Related]

  • 15. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM.
    Ann Rheum Dis; 2010 Jun 12; 69(6):1200-7. PubMed ID: 19773288
    [Abstract] [Full Text] [Related]

  • 16. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 12; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 17. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 12; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 18. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, França IL, Carvalho JF, Sampaio-Barros PD, Goncalves CR, Borba EF, Timenetsky Mdo C, Precioso AR, Duarte A, Bonfa E, Laurindo IM.
    Ann Rheum Dis; 2011 Dec 12; 70(12):2144-7. PubMed ID: 21859696
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D.
    Arthritis Rheum; 2005 Jul 12; 52(7):2146-58. PubMed ID: 15986373
    [Abstract] [Full Text] [Related]

  • 20. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 12; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.